Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16211634 | 0.88 | LTB4R2 (0.44) | LTB4R2HDAC6HDAC1HDAC8NR1H4 | |
| SCHEMBL25981369 | 0.88 | HDAC6 (0.44) | HDAC6HDAC1HDAC8HDAC3 | |
| SCHEMBL25981411 | 0.88 | HDAC6 (0.44) | HDAC6HDAC1HDAC8HDAC3 | |
| SCHEMBL16211386 | 0.88 | HDAC6 (0.51) | LTB4R2HDAC6HDAC1HDAC8HDAC11 | |
| SCHEMBL16211461 | 0.87 | HDAC6 (0.58) | LTB4R2HDAC6HDAC1HDAC8HDAC11 | |
| SCHEMBL23283065 | 0.84 | HDAC1 (0.48) | LTB4R2HDAC6HDAC1HDAC8HDAC11 | |
| SCHEMBL22218401 | 0.83 | LTB4R2 (0.46) | LTB4R2HDAC6HDAC1HDAC8NR1H4 | |
| SCHEMBL23283093 | 0.82 | HDAC6 (0.43) | HDAC6HDAC1HDAC8HDAC11HDAC3 | |
| SCHEMBL28219226 | 0.81 | LTB4R2 (0.41) | LTB4R2HDAC6HDAC1HDAC8NR1H4 | |
| SCHEMBL16221442 | 0.80 | HDAC6 (0.48) | LTB4R2HDAC6HDAC1HDAC8HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | claimed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | claimed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | claimed |
| US-20230248735-A1 | COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-10 | — | — | US | disclosed |
| WO-2023073600-A1 | COMPOSITIONS FOR PREVENTING OR TREATING IDIOPATHIC PULMONARY FIBROSIS (IPF) | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-05-04 | — | — | WO | disclosed |
| US-20210161905-A1 | Compositions for Preventing or Treating Dry Eye | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2021-06-03 | — | — | US | disclosed |
| WO-2021079300-A1 | COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2021-04-29 | — | — | WO | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| EP-2991982-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248735-A1 | COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) | NR1H2, CFTR, CYP11B2 | LTB4R2 23/4885HDAC6 997/4885HDAC1 1635/4885 |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | LTB4R2 4629/4885HDAC6 5/4885HDAC1 1/4885 |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | LTB4R2 4629/4885HDAC6 5/4885HDAC1 1/4885 |
| US-20210161905-A1 | Compositions for Preventing or Treating Dry Eye | PDE6H, PDE6C, PDE6D | LTB4R2 119/4885HDAC6 772/4885HDAC1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.